Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Conduit Pharmaceuticals Inc. (CDT:NASDAQ), powered by AI.
Conduit Pharmaceuticals Inc. is currently trading at $4.08. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Conduit Pharmaceuticals Inc. on Alpha Lenz.
Conduit Pharmaceuticals Inc.'s P/E ratio is -0.0.
“Conduit Pharmaceuticals Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 491.4%.”
Ask for details →Conduit Pharmaceuticals Inc. is an innovative biotechnology company specializing in the development of therapeutic treatments. The primary function of Conduit Pharmaceuticals is to advance clinical phase drug candidates targeting chronic diseases with significant unmet medical needs. Operating within the highly dynamic biotechnology industry, Conduit Pharmaceuticals focuses on leveraging cutting-edge scientific research to create effective therapies that can transform patient care and outcomes. The company's robust research and development pipeline emphasizes novel solutions in disease areas with a high demand for innovative treatments, such as autoimmune disorders and oncology. As a participant in the biotech sector, Conduit Pharmaceuticals plays a pivotal role in addressing critical health challenges, contributing to scientific advancements, and influencing healthcare delivery. By fostering collaborations with research institutions and healthcare entities, it remains at the forefront of transformative drug development, significantly impacting both the pharmaceutical market landscape and patient communities worldwide. With a commitment to scientific excellence and patient-centric innovation, Conduit Pharmaceuticals continues to chart a course aimed at delivering breakthrough therapies poised to meet pressing global health needs.
“Conduit Pharmaceuticals Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 491.4%.”
Ask for details →Conduit Pharmaceuticals Inc. (ticker: CDT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 7 employees. Market cap is $235,848.
The current price is $4.08 with a P/E ratio of -0.01x and P/B of -0.03x.
ROE is 491.37%.